Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients
Unlike direct-acting antivirals, zapnometinib's dual effect highlights its therapeutic potential in the treatment of severe acute viral infections, with favorable antiviral and immunomodulatory properties.
Authors
- Judith M. A. van den Brand (ORCID: https://orcid.org/0000-0001-8420-5406)
- Geert van Amerongen (ORCID: https://orcid.org/0000-0002-5469-6029)
- Stephan Ludwig (ORCID: https://orcid.org/0000-0003-4490-3052)
- Yvonne Füll (ORCID: https://orcid.org/0000-0003-2290-2366)
- Leon de Waal (ORCID: https://orcid.org/0000-0002-7596-7270)
- Andreas Steinhilber
- Viktoria Anselm
- Martín W. Bauer (ORCID: https://orcid.org/0000-0002-0800-8133)
- Stephan Pleschka (ORCID: https://orcid.org/0000-0002-7372-7089)
- Lara M. Schüssele
- Mark W. Delany (ORCID: https://orcid.org/0000-0001-7037-4233)
- Oliver Planz (ORCID: https://orcid.org/0000-0002-3701-943X)
- Hazem Hamza (ORCID: https://orcid.org/0000-0002-9862-5628)
- Helen Hoffmann
- Stephan Stenglein
- Oliver Pötz
Institutions
- University of Applied Sciences Utrecht (NL)
- Utrecht University (NL)
- Justus-Liebig-Universität Gießen (DE)
- Viroclinics Biosciences (Netherlands) (NL)
- National Research Centre (EG)
- NewGen Therapeutics (United States) (US)
- National Water Research Center (EG)
- Institute of Molecular Biology (DE)
- Reutlingen University (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1631721
- Citations
- 2
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Deutsche Forschungsgemeinschaft
- Eberhard Karls Universität Tübingen
- Bundesministerium für Bildung und Forschung